Effects of glucagon on liver metabolism in obesity and diabetes
The Effects of Glucagon on Hepatic Metabolism
This study tests how glucagon affects liver function and metabolism in people with obesity and Type 2 diabetes to see if it can help manage their blood sugar levels better.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 25 Years to 65 Years |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT05500586 on ClinicalTrials.gov |
What this trial studies
This study investigates how glucagon affects liver metabolism, particularly in individuals with obesity and Type 2 diabetes (T2DM). It aims to understand the relationship between glucagon's action on amino acid metabolism and hepatic lipid metabolism in both lean and obese subjects. The research will explore whether glucagon resistance is influenced by obesity, liver fat accumulation, or both, and how this impacts postprandial glucose levels. Participants will undergo glucagon response studies to assess these interactions.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with obesity and Type 2 diabetes or prediabetes who are willing to participate and can provide consent.
Not a fit: Patients with a history of upper abdominal surgery, active systemic illness, or contraindications to MRI may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatments for obesity and Type 2 diabetes by enhancing our understanding of glucagon's role in metabolism.
How similar studies have performed: Other studies have shown promising results in understanding glucagon's role in metabolism, but this specific approach is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Willing to participate * Able to give consent Exclusion Criteria: * History of prior upper abdominal surgery e.g. gastric banding, pyloroplasty, vagotomy. * Active systemic illness or malignancy. * Symptomatic macrovascular or microvascular disease. * Contraindications to MRI (e.g. metal implants, claustrophobia). * Hematocrit \< 35% * TSH \< 0.4 or \> 5.5. * Consumption of \> 2 alcohol drinks per day or \> 14 per week or a positive AUDIT questionnaire
Where this trial is running
Rochester, Minnesota
- Mayo Clinic in Rochester — Rochester, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: Adrian Vella — Mayo Clinic
- Study coordinator: Jeanette Laugen
- Email: Laugen.Jeanette@mayo.edu
- Phone: 5072558110
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.